NCT03455764View on ClinicalTrials.gov

MCS110 With BRAF/MEK Inhibition in Patients With Melanoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

September 10, 2018

Primary Completion Date

September 5, 2023

Study Completion Date

September 5, 2023

Conditions
Melanoma
Interventions
DRUG

MCS110

MCS110 is a colony-stimulating factor-1 (CSF-1) inhibitor. It is a human monoclonal antibody which binds CSF-1.

DRUG

Dabrafenib

Dabrafenib attack different proteins that promote the growth of cancerous cells

DRUG

Trametinib

Trametinib attack different proteins that promote the growth of cancerous cells

Trial Locations (1)

02215

Dana Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT03455764 - MCS110 With BRAF/MEK Inhibition in Patients With Melanoma | Biotech Hunter | Biotech Hunter